Percutaneous coronary intervention vs . medical therapy in patients on dialysis with coronary artery disease in China.

IF 7.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Chinese Medical Journal Pub Date : 2025-02-05 Epub Date: 2024-09-25 DOI:10.1097/CM9.0000000000003295
Enmin Xie, Yaxin Wu, Zixiang Ye, Yong He, Hesong Zeng, Jianfang Luo, Mulei Chen, Wenyue Pang, Yanmin Xu, Chuanyu Gao, Xiaogang Guo, Lin Cai, Qingwei Ji, Yining Yang, Di Wu, Yiqiang Yuan, Jing Wan, Yuliang Ma, Jun Zhang, Zhimin Du, Qing Yang, Jinsong Cheng, Chunhua Ding, Xiang Ma, Chunlin Yin, Zeyuan Fan, Qiang Tang, Yue Li, Lihua Sun, Chengzhi Lu, Jufang Chi, Zhuhua Yao, Yanxiang Gao, Changan Yu, Jingyi Ren, Jingang Zheng
{"title":"Percutaneous coronary intervention vs . medical therapy in patients on dialysis with coronary artery disease in China.","authors":"Enmin Xie, Yaxin Wu, Zixiang Ye, Yong He, Hesong Zeng, Jianfang Luo, Mulei Chen, Wenyue Pang, Yanmin Xu, Chuanyu Gao, Xiaogang Guo, Lin Cai, Qingwei Ji, Yining Yang, Di Wu, Yiqiang Yuan, Jing Wan, Yuliang Ma, Jun Zhang, Zhimin Du, Qing Yang, Jinsong Cheng, Chunhua Ding, Xiang Ma, Chunlin Yin, Zeyuan Fan, Qiang Tang, Yue Li, Lihua Sun, Chengzhi Lu, Jufang Chi, Zhuhua Yao, Yanxiang Gao, Changan Yu, Jingyi Ren, Jingang Zheng","doi":"10.1097/CM9.0000000000003295","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The available evidence regarding the benefits of percutaneous coronary intervention (PCI) on patients receiving dialysis with coronary artery disease (CAD) is limited and inconsistent. This study aimed to evaluate the association between PCI and clinical outcomes as compared with medical therapy alone in patients undergoing dialysis with CAD in China.</p><p><strong>Methods: </strong>This multicenter, retrospective study was conducted in 30 tertiary medical centers across 12 provinces in China from January 2015 to June 2021 to include patients on dialysis with CAD. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Secondary outcomes included all-cause death, the individual components of MACE, and Bleeding Academic Research Consortium criteria types 2, 3, or 5 bleeding. Multivariable Cox proportional hazard models were used to assess the association between PCI and outcomes. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were performed to account for potential between-group differences.</p><p><strong>Results: </strong>Of the 1146 patients on dialysis with significant CAD, 821 (71.6%) underwent PCI. After a median follow-up of 23.0 months, PCI was associated with a 43.0% significantly lower risk for MACE (33.9% [ n  = 278] vs . 43.7% [ n  = 142]; adjusted hazards ratio 0.57, 95% confidence interval 0.45-0.71), along with a slightly increased risk for bleeding outcomes that did not reach statistical significance (11.1% vs . 8.3%; adjusted hazards ratio 1.31, 95% confidence interval, 0.82-2.11). Furthermore, PCI was associated with a significant reduction in all-cause and cardiovascular mortalities. Subgroup analysis did not modify the association of PCI with patient outcomes. These primary findings were consistent across IPTW, PSM, and competing risk analyses.</p><p><strong>Conclusion: </strong>This study indicated that PCI in patients on dialysis with CAD was significantly associated with lower MACE and mortality when comparing with those with medical therapy alone, albeit with a slightly increased risk for bleeding events that did not reach statistical significance.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"301-310"},"PeriodicalIF":7.5000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771592/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CM9.0000000000003295","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The available evidence regarding the benefits of percutaneous coronary intervention (PCI) on patients receiving dialysis with coronary artery disease (CAD) is limited and inconsistent. This study aimed to evaluate the association between PCI and clinical outcomes as compared with medical therapy alone in patients undergoing dialysis with CAD in China.

Methods: This multicenter, retrospective study was conducted in 30 tertiary medical centers across 12 provinces in China from January 2015 to June 2021 to include patients on dialysis with CAD. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Secondary outcomes included all-cause death, the individual components of MACE, and Bleeding Academic Research Consortium criteria types 2, 3, or 5 bleeding. Multivariable Cox proportional hazard models were used to assess the association between PCI and outcomes. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were performed to account for potential between-group differences.

Results: Of the 1146 patients on dialysis with significant CAD, 821 (71.6%) underwent PCI. After a median follow-up of 23.0 months, PCI was associated with a 43.0% significantly lower risk for MACE (33.9% [ n  = 278] vs . 43.7% [ n  = 142]; adjusted hazards ratio 0.57, 95% confidence interval 0.45-0.71), along with a slightly increased risk for bleeding outcomes that did not reach statistical significance (11.1% vs . 8.3%; adjusted hazards ratio 1.31, 95% confidence interval, 0.82-2.11). Furthermore, PCI was associated with a significant reduction in all-cause and cardiovascular mortalities. Subgroup analysis did not modify the association of PCI with patient outcomes. These primary findings were consistent across IPTW, PSM, and competing risk analyses.

Conclusion: This study indicated that PCI in patients on dialysis with CAD was significantly associated with lower MACE and mortality when comparing with those with medical therapy alone, albeit with a slightly increased risk for bleeding events that did not reach statistical significance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中国冠心病透析患者经皮冠状动脉介入治疗与药物治疗的对比。
背景:关于经皮冠状动脉介入治疗(PCI)对患有冠状动脉疾病(CAD)的透析患者的益处,现有证据有限且不一致。本研究旨在评估在中国接受透析治疗的冠状动脉疾病患者中,PCI 与单纯药物治疗之间的关系:这项多中心、回顾性研究于 2015 年 1 月至 2021 年 6 月在中国 12 个省的 30 家三级医疗中心进行,纳入了患有 CAD 的透析患者。主要结果是主要不良心血管事件(MACE),定义为心血管死亡、非致死性心肌梗死和非致死性卒中的复合结果。次要结果包括全因死亡、MACE 的各个组成部分以及出血学术研究联盟标准 2、3 或 5 型出血。多变量考克斯比例危险模型用于评估PCI与预后之间的关系。为了考虑潜在的组间差异,还进行了逆概率治疗加权(IPTW)和倾向评分匹配(PSM):结果:在1146名患有严重CAD的透析患者中,有821人(71.6%)接受了PCI治疗。中位随访 23.0 个月后,PCI 与 MACE 风险显著降低 43.0% 相关(33.9% [ n = 278] vs . 43.7% [ n = 142];调整后危险比为 0.57,95% 置信区间为 0.45-0.71),同时出血风险略有增加,但未达到统计学意义(11.1% vs . 8.3%;调整后危险比为 1.31,95% 置信区间为 0.82-2.11)。此外,PCI 还能显著降低全因死亡率和心血管死亡率。亚组分析并未改变PCI与患者预后的相关性。这些主要研究结果在IPTW、PSM和竞争风险分析中都是一致的:本研究表明,与单纯药物治疗相比,对患有 CAD 的透析患者进行 PCI 治疗可显著降低 MACE 和死亡率,尽管出血事件的风险略有增加,但未达到统计学意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Chinese Medical Journal
Chinese Medical Journal 医学-医学:内科
CiteScore
9.80
自引率
4.90%
发文量
19245
审稿时长
6 months
期刊介绍: The Chinese Medical Journal (CMJ) is published semimonthly in English by the Chinese Medical Association, and is a peer reviewed general medical journal for all doctors, researchers, and health workers regardless of their medical specialty or type of employment. Established in 1887, it is the oldest medical periodical in China and is distributed worldwide. The journal functions as a window into China’s medical sciences and reflects the advances and progress in China’s medical sciences and technology. It serves the objective of international academic exchange. The journal includes Original Articles, Editorial, Review Articles, Medical Progress, Brief Reports, Case Reports, Viewpoint, Clinical Exchange, Letter,and News,etc. CMJ is abstracted or indexed in many databases including Biological Abstracts, Chemical Abstracts, Index Medicus/Medline, Science Citation Index (SCI), Current Contents, Cancerlit, Health Plan & Administration, Embase, Social Scisearch, Aidsline, Toxline, Biocommercial Abstracts, Arts and Humanities Search, Nuclear Science Abstracts, Water Resources Abstracts, Cab Abstracts, Occupation Safety & Health, etc. In 2007, the impact factor of the journal by SCI is 0.636, and the total citation is 2315.
期刊最新文献
Effects of visual impairment and its restoration on electroencephalogram during walking in aged females. Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma. Organ medicine: New concept of life sciences. STAR Recommendations: A novel framework for generating recommendations. Safety of teriflunomide in Chinese adult patients with relapsing multiple sclerosis: A phase IV, 24-week multicenter study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1